Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15Leukemia, Myeloid, Chronic-Phase 3Leukemia, Myeloid 3Leukemia 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Philadelphia Chromosome 2Myeloproliferative Disorders 2Bronchiolitis Obliterans Syndrome 2Hematologic Diseases 1HER2+ Metastatic Breast Cancer 1Blast Crisis 1

Interventions

pirtobrutinib 3Cyclophosphamide 3Azacitidine 3ibrutinib 2fludarabine 2Mycophenolic Acid 2Lenalidomide 2zanubrutinib 1venetoclax 1ruxolitinib 1ponatinib 1nilotinib 1idelalisib 1idecabtagene vicleucel 1fludarabine phosphate 1cedazuridine 1cc-486 1asciminib 1acalabrutinib 1Whole-Body Irradiation 1Vancomycin 1Tretinoin 1Tacrolimus 1Sirolimus 1Semen Analysis 1Rituximab 1Quality of Life 1Physical Examination 1Peripheral Blood Stem Cell Transplantation 1Patient Reported Outcome Measures 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Diseases × asciminib × 90 days × Clear all
NCT03578367 2026-04-21

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.

Novartis

Phase 2 Completed
104 enrolled 33 charts
MyeloidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡